Advances in novel vaccines for foot and mouth disease: focus on recombinant empty capsids

References

• Grubman M, Baxt B. Foot-and-mouth disease. Clin Microbiol Rev. 2004;17:465–493.
   PubMed Web of Science ®Google Scholar
• Knight-Jones TJ, Robinson L, Charleston B, et al. Global foot-and-mouth disease research update and gap analysis: 2 – epidemiology, wildlife and economics. Transbound Emerg Dis. 2016;63:14–29.
   PubMed Web of Science ®Google Scholar
• Barnett P, Geale D, Clarke G, et al. A review of OIE country status recovery using vaccinate-to-live versus vaccinate-to-die foot-and-mouth disease response policies i: benefits of higher potency vaccines and associated NSP DIVA test systems in post-outbreak surveillance. Transbound Emerg Dis. 2015;62:367–387.
   PubMed Web of Science ®Google Scholar
• Geale D, Barnett P, Clarke G, et al. A review of OIE country status recovery using vaccinate-to-live versus vaccinate-to-die foot-and-mouth disease response policies ii: waiting periods after emergency vaccination in FMD free countries. Transbound Emerg Dis. 2015;62:388–406.
   PubMed Web of Science ®Google Scholar
• Doel TR. FMD vaccines. Virus Res. 2003;91:81–99.
   PubMed Web of Science ®Google Scholar
• Parida S. Vaccination against foot-and-mouth disease virus: strategies and effectiveness. Expert Rev Vaccines. 2009;8:347–365.
   PubMed Web of Science ®Google Scholar
• Sobrino F, Dávila M, Ortín J, et al. Multiple genetic variants arise in the course of replication of foot-and-mouth disease virus in cell culture. Virology. 1983;128:310–318.
   PubMed Web of Science ®Google Scholar
• Anil KU, Sreenivasa BP, Mohapatra JK, et al. Sequence analysis of capsid coding region of foot-and-mouth disease virus type A vaccine strain during serial passages in BHK-21 adherent and suspension cells. Biologicals. 2012;40:426–430.
   PubMed Web of Science ®Google Scholar
• Rodriguez LL, Gay CG. Development of vaccines toward the global control and eradication of foot-and-mouth disease. Expert Rev Vaccines. 2011;10:377–387.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang J, Chen H, et al. Research in advance for FMD novel vaccines. Virol J. 2011;8:268–266.
   PubMed Web of Science ®Google Scholar
• Robinson L, Knight-Jones TJ, Charleston B, et al. Global foot-and-mouth disease research update and gap analysis: 3 – vaccines. Transbound Emerg Dis. 2016;63:30–41.
   PubMed Web of Science ®Google Scholar
• Mayr GA, Donnell VO, Chinsangaram J, et al. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs. Vaccine. 2001;19:2152–2162.
   PubMed Web of Science ®Google Scholar
• Yao Q, Qian P, Huang Q, et al. Comparison of immune responses to different foot-and-mouth disease genetically engineered vaccines in guinea pigs. J Virol Methods. 2008;147:143–150.
   PubMed Web of Science ®Google Scholar
• Mignaqui AC, Ruiz V, Perret S, et al. Transient gene expression in serum-free suspension- growing mammalian cells for the production of foot-and- mouth disease virus empty capsids. PLoS One. 2013;8:e72800.
   PubMed Web of Science ®Google Scholar
• Jamal SM, Belsham GJ. Foot-and-mouth disease: past, present and future. Vet Res. 2013;44:116.
   PubMed Web of Science ®Google Scholar
• Belsham G, Botner A. Use of recombinant capsid proteins in the development of a vaccine against the foot-and-mouth disease virus. Virus Adapt Treat. 2015;7:11–23.
   Google Scholar
• Belsham G. Distinctive features of foot-and-mouth disease virus, a member of the picornavirus family; aspects of virus protein synthesis, protein processing and structure. Prog Biophys Mol Biol. 1993;60:241–260.
   PubMed Web of Science ®Google Scholar
• Moscufo N, Simons J, Chow M. Myristoylation is important at multiple stages in poliovirus assembly. J Virol. 1991;65:2372–2380.
   PubMed Web of Science ®Google Scholar
• Ansardi DC, Porter DC, Morrow CD. Myristylation of poliovirus capsid precursor P1 Is required for assembly of subviral particles. J Virol. 1992;66:4556–4563.
   PubMed Web of Science ®Google Scholar
• Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol. 2003;11:438–444.
   PubMed Web of Science ®Google Scholar
• Roy P, Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Hum Vaccin. 2008;4:5–8.
   PubMed Web of Science ®Google Scholar
• Crisci E, Bárcena J, Montoya M. Virus-like particles: The new frontier of vaccines for animal viral infections. Vet Immunol Immunopathol. 2012;148:211–225.
   PubMed Web of Science ®Google Scholar
• Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine. 2012;31:58–83.
   PubMed Web of Science ®Google Scholar
• Lee C, Sun H, Hu S, et al. An improved SUMO fusion protein system for effective production of native proteins. Protein Sci. 2008;17:1241–1248.
   PubMed Web of Science ®Google Scholar
• Guo H, Sun S, Jin Y, et al. Foot-and-mouth disease virus-like particles produced by a SUMO fusion protein system in Escherichia coli induce potent protective immune responses in guinea pigs, swine and cattle. Vet Res. 2013;44:1.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Chen H, Wang Y, et al. Large-scale production of foot-and-mouth disease virus (serotype Asia1) VLP vaccine in Escherichia coli and protection potency evaluation in cattle. BMC Biotechnol. 2016;16:56.
   PubMed Web of Science ®Google Scholar
• Lee C, Yan Y, Liang S, et al. Production of FMDV virus-like particles by a SUMO fusion protein approach in Escherichia coli. J Biomed Sci. 2009;16:69–69.
   PubMed Web of Science ®Google Scholar
• Puckette M, Clark BA, Smith JD, et al. Foot-and-mouth disease (FMD) virus 3C protease mutant L127P: implications for FMD vaccine development. J Virol. 2017;91:e00924–e00917.
   PubMed Web of Science ®Google Scholar
• Ferrer-Miralles N, Domingo-Espín J, Corchero JL, et al. Microbial factories for recombinant pharmaceuticals. Microb Cell Fact. 2009; 8:17.
   PubMed Web of Science ®Google Scholar
• Puckette M, Smith JD, Gabbert L, et al. Production of foot-and-mouth disease virus capsid proteins by the TEV protease. J Biotechnol. 2018;275:7–12.
   PubMed Web of Science ®Google Scholar
• Oem J, Park J, Lee K, et al. Characterization of recombinant foot-and-mouth disease virus pentamer-like structures expressed by baculovirus and their use as diagnostic antigens in a blocking ELISA. Vaccine. 2007;25:4112–4121.
   PubMed Web of Science ®Google Scholar
• Cao Y, Lu Z, Sun J, et al. Synthesis of empty capsid-like particles of Asia I foot-and-mouth disease virus in insect cells and their immunogenicity in guinea pigs. Vet Microbiol. 2009;137:10–17.
   PubMed Web of Science ®Google Scholar
• Porta C, Xu X, Loureiro S, et al. Efficient production of foot-and-mouth disease virus empty capsids in insect cells following down regulation of 3C protease activity. J Virol Methods. 2013;187:406–412.
   PubMed Web of Science ®Google Scholar
• Porta C, Kotecha A, Burman A, et al. Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen. PLoS Pathog. 2013;9:e1003255.
   PubMed Web of Science ®Google Scholar
• Felberbaum RS. The baculovirus expression vector system: a commercial manufacturing platform for viral vaccines and gene therapy vectors. Biotechnol J. 2015;10:702–714.
   PubMed Web of Science ®Google Scholar
• Li Z, Yi Y, Yin X, et al. Expression of foot-and-mouth disease virus capsid proteins in silkworm-baculovirus expression system and its utilization as a subunit vaccine. PLoS One. 2008;3:e2273.
   PubMed Web of Science ®Google Scholar
• Mohana Subramanian B, Madhanmohan M, Sriraman R, et al. Development of foot-and-mouth disease virus (FMDV) serotype O virus-like-particles (VLPs) vaccine and evaluation of its potency. Antiviral Res. 2012;96:288–295.
   PubMed Web of Science ®Google Scholar
• Ruiz V, Mignaqui AC, Nuñez MC, et al. Comparison of strategies for the production of FMDV empty capsids using the baculovirus vector system. Mol Biotechnol. 2014;56:963–970.
   PubMed Web of Science ®Google Scholar
• Cao Y, Sun P, Fu Y, et al. Formation of virus-like particles from O-type foot-and-mouth disease virus in insect cells using codon-optimized synthetic genes. Biotechnol Lett. 2010;32:1223–1229.
   PubMed Web of Science ®Google Scholar
• Brautigam S, Snezhkov E, Bishop DHL. Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3 and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein. Virology. 1993;192:512–524.
   PubMed Web of Science ®Google Scholar
• Li Z, Yin X, Yi Y, et al. FMD subunit vaccine produced using a silkworm-baculovirus expression system: protective efficacy against two type Asia1 isolates in cattle. Vet Microbiol. 2011;149:99–103.
   PubMed Web of Science ®Google Scholar
• Li Z, Yi Y, Yin X, et al. Development of a foot-and-mouth disease virus serotype A empty capsid subunit vaccine using silkworm (Bombyx mori) pupae. PLoS One. 2012;7:e43849.
   PubMed Web of Science ®Google Scholar
• Usami A, Suzuki T, Nagaya H, et al. Silkworm as a host of baculovirus expression. Curr Pharm Biotechnol. 2010;11:246–250.
   PubMed Web of Science ®Google Scholar
• Usami A, Ishiyama S, Enomoto C, et al. Comparison of recombinant protein expression in a baculovirus system in insect cells (Sf9) and silkworm. J Biochem. 2011;149:219–227.
   PubMed Web of Science ®Google Scholar
• Belsham GJ, Abrams CC, King AMQ, et al. Myristoylation of foot-and-mouth disease virus capsid protein precursors is independent of other viral proteins and occurs in both mammalian and insect cells. J Gen Virol. 1991;72:747–751.
   PubMed Web of Science ®Google Scholar
• Bhat SA, Saravanan P, Hosamani M, et al. Novel immunogenic baculovirus expressed virus-like particles of foot- and-mouth disease (FMD) virus protect guinea pigs against challenge. Res Vet Sci. 2013;95:1217–1223.
   PubMed Web of Science ®Google Scholar
• Srinivas MV, Basagoudanavar SH, Hosamani M. IRES mediated expression of viral 3C protease for enhancing the yield of FMDV empty capsids using baculovirus system. Biologicals. 2016;44:64–68.
   PubMed Web of Science ®Google Scholar
• Li H, Li Z, Xie Y, et al. Novel chimeric foot-and-mouth disease virus-like particles harboring serotype O VP1 protect guinea pigs against challenge. Vet Microbiol. 2016;183:92–96.
   PubMed Web of Science ®Google Scholar
• Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol. 2004;22:1393–1398.
   PubMed Web of Science ®Google Scholar
• Butler M. Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl Microbiol Biotechnol. 2005;68:283–291.
   PubMed Web of Science ®Google Scholar
• Durocher Y, Butler M. Expression systems for therapeutic glycoprotein production. Curr Opin Biotechnol. 2009;20:700–707.
   PubMed Web of Science ®Google Scholar
• Lalonde M, Durocher Y. Therapeutic glycoprotein production in mammalian cells. J Biotechnol. 2017;251:128–140.
   PubMed Web of Science ®Google Scholar
• Pham PL, Kamen A, Durocher Y. Large-scale transfection of mammalian cells for the fast production of recombinant protein. Mol Biotechnol. 2006;34:225–237.
   PubMed Web of Science ®Google Scholar
• Mignaqui AC, Ruiz V, Wigdorovitz A. Comparison of transient and stable expression of foot-and-mouth disease virus capsid proteins in mammalian cells. ABB. 2013;04:1024–1029.
   Google Scholar
• Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 2002;30:1–9.
   PubMed Web of Science ®Google Scholar
• Raymond C, Tom R, Perret S, et al. A simplified polyethylenimine-mediated transfection process for large-scale and high-throughput applications. Methods. 2011;55:44–51.
   PubMed Web of Science ®Google Scholar
• Delafosse L, Xu P, Durocher Y. Comparative study of polyethylenimines for transient gene expression in mammalian HEK293 and CHO cells. J Biotechnol. 2016;227:103–111.
   PubMed Web of Science ®Google Scholar
• Polacek C, Gullberg M, Li J, et al. Low levels of foot-and-mouth disease virus 3C protease expression are required to achieve optimal capsid protein expression and processing in mammalian cells. J Gen Virol. 2013;94:1249–1258.
   PubMed Web of Science ®Google Scholar
• Gullberg M, Muszynski B, Organtini LJ, et al. Assembly and characterization of foot-and-mouth disease virus empty capsid particles expressed within mammalian cells. J Gen Virol. 2013;94:1769–1779.
   PubMed Web of Science ®Google Scholar
• Sweeney TR, Roqué-Rosell N, Birtley JR, et al. Structural and mutagenic analysis of foot-and-mouth disease virus 3C protease reveals the role of the betta-ribbon in proteolysis. J Virol. 2007;81:115–124.
   PubMed Web of Science ®Google Scholar
• Gullberg M, Lohse L, Anette B, et al. A prime-boost vaccination strategy in cattle to prevent foot-and-mouth disease using a “single-cycle” alphavirus vector and empty capsid particles. PLoS One. 2016;11:e0157435.
   PubMed Web of Science ®Google Scholar
• Ruiz V, Mozgovoj MV, Dus Santos MJ, et al. Plant-produced viral bovine vaccines: what happened during the last 10 years? Plant Biotechnol J. 2015;13:1071–1077.
   PubMed Web of Science ®Google Scholar
• Dus Santos MJ, Carrillo C, Ardila F, et al. Development of transgenic alfalfa plants containing the foot and mouth disease virus structural polyprotein gene P1 and its utilization as an experimental immunogen. Vaccine. 2005;23:1838–1843.
   PubMed Web of Science ®Google Scholar
• Pan L, Zhang Y, Wang Y, et al. Foliar extracts from transgenic tomato plants expressing the structural polyprotein P1-2A and protease 3C from foot-and-mouth disease virus elicit a protective response in guinea pigs. Vet Immunol Immunopathol. 2008;121:83–90.
   PubMed Web of Science ®Google Scholar
• Gurunathan S, Wu C, Freidag BL, et al. DNA vaccines: a key for inducing long-term cellular immunity. Curr Opin Immunol. 2000;12:442–447.
   PubMed Web of Science ®Google Scholar
• Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. Vaccines (Basel). 2014;2:624–641.
   PubMedGoogle Scholar
• Mccullough KC, Simone FDE, Brocchi E, et al. Protective immune response against foot-and-mouth disease. J Virol. 1992;66:1835–1840.
   PubMed Web of Science ®Google Scholar
• Doel TR. Natural and vaccine-induced immunity to foot and mouth disease: the prospects for improved vaccines. Rev - off Int Epizoot. 1996;15:883–911.
   PubMed Web of Science ®Google Scholar
• Jorritsma SHT, Gowans EJ, Grubor-Bauk B, et al. Delivery methods to increase cellular uptake and immunogenicity of DNA vaccines. Vaccine. 2016;34:5488–5494.
   PubMed Web of Science ®Google Scholar
• Grunwald T, Ulbert S. Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine- platforms for the battle against infectious diseases. Clin Exp Vaccine Res. 2015;4:1–10.
   PubMed Web of Science ®Google Scholar
• Dory D, Rémond M, Béven V, et al. Foot-and-mouth disease virus neutralizing antibodies production induced by pcDNA3 and Sindbis virus based plasmid encoding FMDV P1-2A3C3D in swine. Antiviral Res. 2009;83:45–52.
   PubMed Web of Science ®Google Scholar
• Fowler V, Robinson L, Bankowski B, et al. A DNA vaccination regime including protein boost and electroporation protects cattle against foot-and-mouth disease. Antiviral Res. 2012;94:25–34.
   PubMed Web of Science ®Google Scholar
• Benvenisti L, Rogel A, Kuznetzova L, et al. Gene gun-mediate DNA vaccination against foot-and-mouth disease virus. Vaccine. 2001;19:3885–3895.
   PubMed Web of Science ®Google Scholar
• Mingxiao M, Ningyi J, Hui Juan L, et al. Immunogenicity of plasmids encoding P12A and 3C of FMDV and swine IL-18. Antiviral Res. 2007;76:59–67.
   PubMed Web of Science ®Google Scholar
• Kotla S, Vishanath BS, Dechamma HJ, et al. DNA vaccine (P1-2A-3C-pCDNA) co-administered with bovine IL-18 gives protective immune response against foot and mouth disease in cattle. Vet Microbiol. 2016;193:106–115.
   PubMed Web of Science ®Google Scholar
• Li Y, Stirling CMA, Denyer MS, et al. Dramatic improvement in FMD DNA vaccine efficacy and cross-serotype antibody induction in pigs following a protein boost. Vaccine. 2008;26:2647–2656.
   PubMed Web of Science ®Google Scholar
• Niborski I, Li Y, Brennan F, et al. Efficacy of particle-based DNA delivery for vaccination of sheep against FMDV. Vaccine. 2006;24:7204–7213.
   PubMed Web of Science ®Google Scholar
• Joyappa DH, Kumar CA, Banumathi N, et al. Calcium phosphate nanoparticle prepared with foot and mouth disease virus P1-3CD gene construct protects mice and guinea pigs against the challenge virus. Vet Microbiol. 2009;139:58–66.
   PubMed Web of Science ®Google Scholar
• Cedillo-Barrón L, Foster-cuevas M, Belsham GJ, et al. Induction of a protective response in swine vaccinated with DNA encoding foot-and-mouth disease virus empty capsid proteins and the 3D RNA polymerase. J Gen Virol. 2001;82:1713–1724.
   PubMed Web of Science ®Google Scholar
• Li Y, Aggarwal N, Takamatsu H, et al. Enhancing immune responses against a plasmid DNA vaccine encoding a FMDV empty capsid from serotype O. Vaccine. 2006;24:4602–4606.
   PubMed Web of Science ®Google Scholar
• Siva Reddy K, Muralidhar Rao D, Badrinaryana N, et al. Enhancement of DNA vaccine (P12A3C-pcDNA) efficacy against foot-and-mouth disease by coadministration of interleukin-18-expressing (IL18 pcDNA) plasmid in guinea-pigs. FEMS Immunol Med Microbiol. 2010;60:261–269.
   PubMedGoogle Scholar
• Sasaki S, Takeshita F, Xin K, et al. Adjuvant formulations and delivery systems for DNA vaccines. Methods. 2003;31:243–254.
   PubMed Web of Science ®Google Scholar
• Peubez I, Chaudet N, Mignon C, et al. Antibiotic-free selection in E. coli: new considerations for optimal design and improved production. Microb Cell Fact. 2010;9:65.
   PubMed Web of Science ®Google Scholar
• Choi Y, Chang J. Viral vectors for vaccine applications. Clin Exp Vaccine Res. 2013;2:97–105.
   PubMedGoogle Scholar
• Brun A, Bárcena J, Blanco E, et al. Current strategies for subunit and genetic viral veterinary vaccine development. Virus Res. 2011;157:1–12.
   PubMed Web of Science ®Google Scholar
• Ferreira TB, Alves PM, Aunins JG, et al. Use of adenoviral vectors as veterinary vaccines. Gene Ther. 2005;12:73–83.
   PubMed Web of Science ®Google Scholar
• Saxena M, Van TTH, Baird FJ, et al. Pre-existing immunity against vaccine vectors – friend or foe? Microbiology. 2013;159:1–11.
   PubMed Web of Science ®Google Scholar
• Zhang K, Huang J, Wang Q, et al. Recombinant pseudorabies virus expressing P12A and 3C of FMDV can partially protect piglets against FMDV challengel. Res Vet Sci. 2011;91:90–94.
   PubMed Web of Science ®Google Scholar
• Schutta C, Barrera J, Pisano M, et al. Multiple efficacy studies of an adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle using homologous challenge. Vaccine. 2016;34:3214–3220.
   PubMed Web of Science ®Google Scholar
• Wu Q, Moraes MP, Grubman MJ. Recombinant adenovirus co-expressing capsid proteins of two serotypes of foot-and-mouth disease virus (FMDV): in vitro characterization and induction of neutralizing antibodies against FMDV in swine. Virus Res. 2003;93:211–219.
   PubMed Web of Science ®Google Scholar
• Moraes MP, Chinsangaram J, Brum MCS, et al. Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine. Vaccine. 2003;22:268–279.
   PubMed Web of Science ®Google Scholar
• Pena L, Moraes MP, Koster M, et al. Delivery of a foot-and-mouth disease virus empty capsid subunit antigen with nonstructural protein 2B improves protection of swine. Vaccine. 2008;26:5689–5699.
   PubMed Web of Science ®Google Scholar
• D’Antuono A, Laimbacher AS, La Torre J, et al. HSV-1 amplicon vectors that direct the in situ production of foot-and-mouth disease virus antigens in mammalian cells can be used for genetic immunization. Vaccine. 2010;28:7363–7372.
   PubMed Web of Science ®Google Scholar
• Romanutti C, Antuono AD, Palacios C, et al. Evaluation of the immune response elicited by vaccination with viral vectors encoding FMDV capsid proteins and boosted with inactivated virus. Vet Microbiol. 2013;165:333–340.
   PubMed Web of Science ®Google Scholar
• Cao Y, Lu Z, Sun P, et al. A pseudotype baculovirus expressing the capsid protein of foot-and-mouth disease virus and a T-cell immunogen shows enhanced immunogenicity in mice. Virol J. 2011;8:77.
   PubMed Web of Science ®Google Scholar
• Zheng M, Jin N, Zhang H, et al. Construction and immunogenicity of a recombinant fowlpox virus containing the capsid and 3C protease coding regions of foot-and-mouth disease virus. J Virol Methods. 2006;136:230–237.
   PubMed Web of Science ®Google Scholar
• De Avila Botton S, Brum MCS, Bautista E, et al. Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon alpha. Vaccine. 2006;24:3446–3456.
   PubMed Web of Science ®Google Scholar
• Lu Z, Bao H, Cao Y, et al. Protection of guinea pigs and swine by a recombinant adenovirus expressing O serotype of foot-and-mouth disease virus whole capsid and 3C protease. Vaccine. 2008;26:48–53.
   PubMed Web of Science ®Google Scholar
• Mayr GA, Chinsangaram J, Grubman MJ. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. Virology. 1999;263:496–506.
   PubMed Web of Science ®Google Scholar
• Pacheco JM, Brum MCS, Moraes MP, et al. Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine. Virology. 2005;337:205–209.
   PubMed Web of Science ®Google Scholar
• Moraes M, Mayr G, Mason P, et al. Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine. 2002;20:1631–1639.
   PubMed Web of Science ®Google Scholar
• Moraes MP, Segundo FD-S, Dias CC, et al. Increased efficacy of an adenovirus-vectored foot-and-mouth disease capsid subunit vaccine expressing nonstructural protein 2B is associated with a specific T cell response. Vaccine. 2011;29:9431–9440.
   PubMed Web of Science ®Google Scholar
• Fernandez-Sainz I, Medina GN, Ramirez-Medina E, et al. Adenovirus-vectored foot-and-mouth disease vaccine confers early and full protection against FMDV O1 Manisa in swine. Virology. 2017;502:123–132.
   PubMed Web of Science ®Google Scholar
• Diaz-San Segundo F, Montiela NA, Sturzaa DF, et al. Combination of Adt-O1Manisa and Ad5-boIFNλ3 induces early protective immunity against foot-and-mouth disease in cattle. Virology. 2016;499:340–349.
   PubMed Web of Science ®Google Scholar
• Sreenivasa BP, Mohapatra JK, Pauszek SJ, et al. Recombinant human adenovirus-5 expressing capsid proteins of Indian vaccine strains of foot-and-mouth disease virus elicits effective antibody response in cattle. Vet Microbiol. 2017;203:196–201.
   PubMed Web of Science ®Google Scholar
• Capozzo AVE, Burke DJ, Fox JW, et al. Expression of foot and mouth disease virus non-structural polypeptide 3ABC induces histone H3 cleavage in BHK21 cells. Virus Res. 2002;90:91–99.
   PubMed Web of Science ®Google Scholar
• Bablanian GM, Grubman MJ. Characterization of the foot-and-mouth disease virus 3C protease expressed in Escherichia coli . Virology. 1993;197:320–327.
   PubMed Web of Science ®Google Scholar
• Strong R, Belsham GJ. Sequential modification of translation initiation factor eIF4GI by two different foot-and-mouth disease virus proteases within infected baby hamster kidney cells: identification of the 3Cpro cleavage site. J Gen Virol. 2004;85:2953–2962.
   PubMed Web of Science ®Google Scholar
• Rweyemamu MM, Terry G, Pay TWF. Stability and immunogenicity of empty particles of foot-and-mouth disease virus. Arch Virol. 1979;59:69–79.
   PubMed Web of Science ®Google Scholar
• Kotecha A, Seago J, Scott K, et al. Structure-based energetics of protein interfaces guides foot-and-mouth disease virus vaccine design. Nat Struct Mol Biol. 2015;22:788–794.
   PubMed Web of Science ®Google Scholar
• Grubman MJ, Moraes MP, Schutta C, et al. Adenovirus serotype 5-vectored foot-and-mouth disease subunit vaccines: the first decade. Future Virol. 2010;5:51–64.
   Web of Science ®Google Scholar
• Chan V. Use of genetically modified viruses and genetically engineered virus-vector vaccines: environmental effects. J Toxicol Env Heal. 2006;69:1971–1977.
   PubMed Web of Science ®Google Scholar